| Literature DB >> 30105290 |
Mouen A Khashab1, Pietro Familiari2, Peter V Draganov3, Hanaa Dakour Aridi1, Joo Young Cho4, Michael Ujiki5, Ricardo Rio Tinto6, Hubert Louis6, Pankaj N Desai7, Vic Velanovich8, Eduardo Albéniz9, Amyn Haji10, Jeffrey Marks11, Guido Costamagna2, Jacques Devière6, Yaseen Perbtani3, Mason Hedberg5, Fermin Estremera9, Luis A Martin Del Campo11, Dennis Yang3, Majidah Bukhari1, Olaya Brewer1, Omid Sanaei1, Lea Fayad1, Amol Agarwal1, Vivek Kumbhari1, Yen-I Chen1,12.
Abstract
BACKGROUND AND STUDY AIMS: The efficacy of per oral endoscopic myotomy (POEM) in non-achalasia esophageal motility disorders such as esophagogastric junction outflow obstruction (EGJOO), diffuse esophageal spasm (DES), and jackhammer esophagus (JE) has not been well demonstrated. The aim of this international multicenter study was to assess clinical outcomes of POEM in patients with non-achalasia disorders, namely DES, JE, and EGJOO, in a large cohort of patients. PATIENTS AND METHODS: This was a retrospective study at 11 centers. Consecutive patients who underwent POEM for EGJOO, DES, or JE between 1/2014 and 9/2016 were included. Rates of technical success (completion of myotomy), clinical response (symptom improvement/Eckardt score ≤ 3), and adverse events (AEs, severity per ASGE lexicon) were ascertained .Entities:
Year: 2018 PMID: 30105290 PMCID: PMC6086680 DOI: 10.1055/a-0625-6288
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1 aHigh-resolution manometry with findings consistent with jackhammer esophagus (distal contractile integral > 8000 mmHg-s-cm). b Per oral endoscopic myotomy with long myotomy (17 cm) for management of jackhammer esophagus
Baseline characteristics.
| Age (years, mean [SD]) | 61.7 (16.3) |
| Gender | |
| Female n = (%) | 28 (56.0) |
| Male n = (%) | 22 (44.0) |
| Duration of symptoms (months, mean [SD]) | 53.2 (84.4) |
|
Chest pain
| 36 (76.6) |
| None | 11 (23.4) |
| Occasional | 13 (27.7) |
| Daily | 11 (23.4) |
| Each Meal | 12 (25.5) |
| Total Eckardt Score, mean (SD)/median (IQR) | 6.9 (2.3)/7 (5 – 8) |
| Medical therapy (some patients on more than one) n = (%) | 20 (40.0) |
| Calcium channel blocker (CCB) | 16 (32.0) |
| Nitric oxide | 7 (14.0) |
| Tricyclics | 1 (2.0) |
| Others | 2 (4.0) |
| Endoscopic treatment-naïve n = (%) | 36 (72.0) |
| Prior botulinum toxin injection and pneumatic dilation n = (%) | 1 (2.0) |
| Prior pneumatic dilation alone n = (%) | 7 (14.0) |
| Prior botulinum toxin injection alone n = (%) | 4 (8.0) |
| Prior pneumatic dilation and Heller myotomy n = (%) | 1(2.0) |
| Prior botulinum toxin injection and Heller myotomy n = (%) | 1 (2.0) |
SD, standard deviation; IQR, interquartile range
Fig. 2Adverse events stratified according to severity as per the ASGE Lexicon 18 .
Clinical outcomes stratified according to type of esophageal motility disorder.
| Outcome | EGJOO | DES/JH |
|
| (n = 15) | (m = 35) | ||
| Improvements in chest pain (%, 95 %CI) | 88.9 (51.7 – 99.7) | 87 (66.4 – 97.2) | 0.88 |
| Clinical success (%, 95 %CI) | 93.3 (68.1 – 99.8) | 84.9 (68.1 – 94.9) | 0.41 |
| Mean post POEM Eckardt score, mean (95 % CI) | 1.0 (0.55 – 1.68) | 1.9 (1.41 – 2.42) | 0.24 |
| Post-POEM symptomatic reflux (%, 95 %CI) | 35.7 (12.8 – 64.9) | 16.1 (5.5 – 33.7) | 0.14 |
| Median length of hospitalization (days, IQR) | 3 (1 – 4) | 2 (1.5 – 5.5) | 0.85 |
| Median length of follow-up (days, IQR) | 195 (139 – 617) | 272 (36 – 500) | 0.96 |
| HRM performed post-POEM (%, 95 %CI) | 93.3 (68.1 – 99.8) | 60 (42.1 – 76.1) | 0.02 |
| Resolution of EGJOO/DES/JE on post-procedure HRM (%, 95 %CI) | 71.4 (41.9 – 91.6) | 90.5 (69.6 – 98.8) | 0.14 |
| Adverse events (%, 95 %CI) | 13.3 (1.6 – 40.4) | 20 (8.4 – 36.9) | 0.71 |
SD, standard deviation; IQR, interquartile range; POEM, per oral endoscopic myotomy; EGJOO, esophagogastric junction outflow obstruction; DES, diffuse esophageal spasm; JE: jackhammer esophagus; HRM, high-resolution manometry